Quantcast

Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org

July 26, 2014

MarketOptimizer.org adds “Multiple Sclerosis Global Clinical Trials Review, H2, 2014” to its store. Inquire before buying at http://www.marketoptimizer.org/contacts/inquire-before-buying?rname=9010.

Dallas, TX (PRWEB) July 26, 2014

Multiple sclerosis (MS), also known as disseminated sclerosis or encephalomyelitis disseminata, is an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a wide range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. Multiple sclerosis takes several forms, with new symptoms either occurring in isolated attacks (relapsing forms) or building up over time (progressive forms). Between attacks, symptoms may disappear completely; however, permanent neurological problems often occur, especially as the disease advances.

Complete report details at http://www.marketoptimizer.org/multiple-sclerosis-global-clinical-trials-review-h2-2014.html.

Top Companies Participating in Multiple Sclerosis Therapeutics Clinical Trials:

  •     Prominent Drugs
  •     Biogen Idec Inc.
  •     E. Merck KG
  •     Novartis AG
  •     Teva Pharmaceutical Industries Limited
  •     Bayer AG
  •     Sanofi
  •     GlaxoSmithKline plc
  •     Acorda Therapeutics, Inc.
  •     Elan Corporation, plc
  •     Pfizer Inc.

“Multiple Sclerosis Global Clinical Trials Review, H2, 2014″ provides data on the Multiple Sclerosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Multiple Sclerosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Multiple Sclerosis.

Order a purchase copy at http://www.marketoptimizer.org/contacts/purchase?rname=9010.

Scope

  •     Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  •     Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  •     Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  •     Understand the dynamics of a particular indication in a condensed manner
  •     Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  •     Obtain discontinued trial listing for trials across the globe
  •     Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

List of Tables

Multiple Sclerosis Therapeutics, Global, Clinical Trials by Region, 2014* 7

Multiple Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8

Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9

Multiple Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10

Multiple Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11

Multiple Sclerosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12

Multiple Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13

Multiple Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14

Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15

Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16

Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17

Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18

Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19

Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20

Multiple Sclerosis Therapeutics, Global, Clinical Trials by Phase, 2014* 21

Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22

Multiple Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23

Multiple Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24

Multiple Sclerosis Therapeutics, Global, Suspended Clinical Trials, 2014* 25

Multiple Sclerosis Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26

Multiple Sclerosis Therapeutics, Global, Terminated Clinical Trials, 2014* 28

Multiple Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 35

Multiple Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 36

Multiple Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 37

Multiple Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 39

Multiple Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 40

Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Biogen Idec Inc., 2014* 43

Explore more reports on Pharmaceuticals industry at http://www.marketoptimizer.org/category/life-sciences/pharmaceuticals.

About Us:

MarketOptimizer.org is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

For the original version on PRWeb visit: http://www.prweb.com/releases/multiple-sclerosis-global/clinical-trials-2014/prweb12047419.htm


Source: prweb



comments powered by Disqus